Journal of Immunology Research

Journal of Immunology Research / 2012 / Article
Special Issue

Immunological Aspects of Human Reproduction

View this Special Issue

Review Article | Open Access

Volume 2012 |Article ID 258391 |

Shyi-Jou Chen, Yung-Liang Liu, Huey-Kang Sytwu, "Immunologic Regulation in Pregnancy: From Mechanism to Therapeutic Strategy for Immunomodulation", Journal of Immunology Research, vol. 2012, Article ID 258391, 10 pages, 2012.

Immunologic Regulation in Pregnancy: From Mechanism to Therapeutic Strategy for Immunomodulation

Academic Editor: Raivo Uibo
Received12 Jul 2011
Revised04 Sep 2011
Accepted16 Sep 2011
Published03 Nov 2011


The immunologic interaction between the fetus and the mother is a paradoxical communication that is regulated by fetal antigen presentation and/or by recognition of and reaction to these antigens by the maternal immune system. There have been significant advances in understanding of abnormalities in the maternal-fetal immunologic relationship in the placental bed that can lead to pregnancy disorders. Moreover, immunologic recognition of pregnancy is vital for the maintenance of gestation, and inadequate recognition of fetal antigens may cause abortion. In this paper, we illustrate the complex immunologic aspects of human reproduction in terms of the role of human leukocyte antigen (HLA), immune cells, cytokines and chemokines, and the balance of immunity in pregnancy. In addition, we review the immunologic processes of human reproduction and the current immunologic therapeutic strategies for pathological disorders of pregnancy.

1. Introduction

In 1953, Medawar first proposed the concept of immune tolerance, giving as an example the case of the fetal allograft [1, 2]. He addressed the hypothesis that the semiallogeneic fetus is able to survive because the immunologic interaction between mother and fetus is regulated and inhibited, and that this is because of either a lack of fetal antigen expression resulting from the anatomic separation of the mother from the fetus or a functional suppression of maternal lymphocytes. The exact mechanisms required to induce immunologic tolerance of the fetus are not entirely understood. Despite close contact between fetal trophoblasts and maternal immune cells, there is a lack of antigen stimulation of maternal lymphocytes [35].

Successful pregnancy has been considered a biologic example of semiallogeneic graft acceptance, in which the semiallogeneic fetus is protected from immune attack from the mother. Interestingly, the so-called semiallogeneic conceptus actually consists of the trophoblast cells at the maternal-conceptus interface [6]. During the first trimester of human pregnancy, the placenta develops into a dividing villous formation with differentiation of characteristic trophoblast cell types having different functions. Cytotrophoblast progenitors found in the villi follow two differentiation pathways: some fuse to form the multinucleated syncytiotrophoblast layer that encases the floating villi of the placenta, providing the interface with maternal blood to regulate oxygen and protein transport [7], while others follow an invasive pathway and differentiate into extravillous trophoblast (EVT) cells [8]. These cells migrate from the villous tips in columns that anchor the placenta to the maternal decidua, and EVT cells form the cytotrophoblast shield over the decidua as well as migrating and invading the decidua. Invasive EVT cells play an active role in the remodeling processes that occur in the uterine spiral arteries [9]. In human hemochorial placenta, fetal trophoblast cells appear to be in extremely close contact with the maternal immune cells, based on the observation that EVT cells invade the maternal decidua. Thus, immunologic interrelations between mother and fetus during pregnancy are thought to occur in the decidua [10, 11]. The invasive competence of EVT cells is most dominant during the first trimester and declines afterward.

The major cellular component of the decidua is decidual stromal cells (DSCs). DSCs exert different immune activities that have emerged as relevant to the immunologic interaction between mother and fetus and may lead to either a normal pregnancy or abortion [12, 13]. Recent attention has focused on current knowledge of the effects of pregnancy on the immune response, both peripherally and in the decidua, leading to a discussion on fetal mechanisms for escaping maternal immune attack and the development of immunomodulatory therapeutic strategies for reproductive problems [14]. Understanding the immunologic processes that occur in normal conception will significantly improve our awareness of pathological conditions and suggest strategies to manage associated human reproductive disorders such as abortion, preeclampsia, and preterm delivery [15].

2. Alteration of Human Leukocyte Antigen Expression during Pregnancy

Human leukocyte antigens (HLAs) are also called “transplantation” antigens because they comprise the most powerful stimulators of graft rejection. However, novel HLAs expressed in the fetal membranes are tolerogenic rather than immunogenic [16, 17], and although anti-paternal HLA antibodies are common in pregnant women, they do no damage [18]. One of the fundamental and absorbing paradoxes of life is the immunologic tolerance during reproduction involving the survival and symbiosis of the genetically distinct fetus and its mother [5]. Thus, the mechanisms underlying maternal tolerance are usually effective and raise the essential issue of how immune privilege might be established under the natural conditions of pregnancy to guarantee viability of the embryo/fetus [1921].

The expression of major histocompatibility complex (MHC) proteins at the interface between mother and fetus is tightly controlled in mammalian pregnancy [22]. The expressed MHC class I genes are subdivided into class Ia, which includes HLA-A, -B, and -C and class Ib, which includes HLA-E, -F, and -G. HLA class II (HLA-D) genes are not translated in human trophoblast cells even under inducing conditions where they are transcribed [23, 24] and MHC class II is also undetected in both villous and extra-villous human trophoblast cells [25]. Human trophoblast cells express one MHC class Ia molecule (HLA-C) and all three class Ib molecules. In human placenta, the cell-surface expression of MHC class I molecules by the fetal trophoblast is limited to loci of low polymorphism, HLA-G, HLA-E, and HLA-C [26, 27], but the fetal trophoblast cells do not express the MHC class Ia antigens HLA-A and HLA-B [19, 28] that are responsible for the rapid rejection of allografts in humans. The HLA-C gene is moderately polymorphic and could possibly stimulate maternal antifetal acquired immunity if the paternal alleles differ from the maternal. Interactions between HLA-C and decidual natural killer (NK) cells may also facilitate trophoblast invasion into maternal tissue: Tilburgs et al. demonstrated that pregnancies with an HLA-C-mismatched child induce an increased percentage of activated T cells in decidual tissue. In addition, HLA-C-mismatched pregnancies exhibit a decidual lymphocyte response to fetal cells and contain functional regulatory T cells in decidual tissue, whereas HLA-C-matched pregnancies do not. This suggests that in uncomplicated pregnancies, decidual T cells exclusively recognize fetal HLA-C at the maternal-fetal boundary, but are prevented from inducing a destructive immune response [29]. Despite this, allelic differences at the HLA-C locus do not seem to be a contributory factor in infertility or termination of pregnancy.

HLA-G was the first of the HLA class Ib molecules expressed by trophoblast cells to be identified and remains an antigen of great interest and a focus of experimental evaluation [19, 20, 30]. Understanding the molecular and biochemical features of the HLA-G gene and its products may improve our ability to determine the ways in which HLA-G can affect pregnancy [31]. Multiple reports indicate that levels of HLA-G may predicate reproductive success [20, 32, 33]. As a consequence, fertility physicians are anxious to identify commercially available enzyme-linked immunosorbent assays or other assays that will accurately report levels of HLA-G in the blood of patients with suboptimal fertility [31].

Although it has been proposed that HLA-G may be an evolutionary artifact without function [34], recent studies using HLA-G proteins from transfected cells indicate that these proteins may regulate immune cells and thus may be integral to immune privilege in pregnancy [20, 35]. HLA-G proteins probably target all of the major immune cell subsets [33, 35, 36]. Moreover, Blanco et al. showed that the expression of HLA-G by DSC preserved their potential to control the cytotoxic activity of NK cells against trophoblast and the physiological decay (by apoptosis) of DSC [15].

In the following, we discuss further the complex immune interactions of human reproduction. We describe the activities in pregnancy of lymphocytes, NK cells, uterine (u)NK cells, chemokines, and antigen-presenting cells (APCs) including macrophages.

3. Trophoblast Cells and Immunologic Balance during Pregnancy

An essential issue in pregnancy is how the fetal-placental unit escapes maternal immune rejection. Although fetal and maternal cells interact throughout pregnancy, the fetus naturally continues as a privileged site not subject to rejection [37, 38]. In most of the species that have been studied, expression of MHC molecules by trophoblast cells is repressed, apparently as a strategy to avoid recognition and destruction by the maternal immune system. In recent years, studies of equine pregnancy have advanced the field of reproductive immunology [39]. The trophoblast cells of the horse are unique in the combination of spatial and temporal regulation of MHC expression that they exhibit during placentation. The allantochorion trophoblasts, which comprise the majority of the maternal-fetal interface, do not express MHC class I proteins, although some mRNA can be detected in these cells [40]. During a short window in early pregnancy, the trophoblasts of the chorionic girdle and endometrial cups transiently express very high levels of polymorphic MHC class I antigens of both maternal and paternal origin [41]. The transcription of both polymorphic and nonpolymorphic MHC class I loci in invasive trophoblasts and the high levels of cell-surface expression of the polymorphic antigens set apart the equine model. Maternal and paternal MHC antigens are both expressed on horse trophoblast, and the mare frequently produces cytotoxic antibodies to the paternal alloantigen shortly after chorionic girdle trophoblast invasion [41]. The expression of HLA-G and HLA-E antigens by the trophoblast may also inhibit cytolysis by natural killer cells [42, 43]. Bacon et al. further demonstrated that, in the equine model, functional alloantigen presentation by the trophoblast can be a normal part of early pregnancy [40].

Peripheral blood lymphocytes isolated from pregnant mares demonstrate a reduced capacity to develop into effector cytotoxic T lymphocytes capable of lysing target cells from the breeding stallion [44]. This reduction in T-cell-mediated alloreactivity reverts after parturition or pregnancy termination and is not observed in males or nonpregnant females. Work by several groups has demonstrated trophoblast-produced soluble factors that may create such an environment by modulating the proliferation and blastogenesis of maternal lymphocytes. Extracts from day 80 placenta have been shown to inhibit the proliferation of maternal lymphocytes, and coculture of chorionic girdle trophoblasts with maternal lymphocytes caused a decrease in proliferation and a reduction in cytokine production [45, 46]. In conclusion, the pregnant mare’s immune responses to the trophoblast of her developing placenta are fascinating in their complexity. By providing a window into the nature of maternal-fetal interactions, the horse has illuminated immunologic events not easily detectable in other species.

It is well recognized that there is intimate contact between maternal tissue and the EVT cells that invade the decidua, and that there are high numbers of different types of leukocytes present within the stromal compartment of the luteal-phase endometrium, which increase in first-trimester decidua [10, 47]. Human decidua contain abundant immune cells during gestation, with more than 30% of stromal cells in first-trimester decidua expressing the leukocyte common antigen CD45 [10]. There are four major populations of decidua leucocytes present in early pregnancy: uNK cells, macrophages, dendritic cells (DC), and T cells [48]. Among these, the most abundant are uNK cells (CD56+CD16 NK cells), macrophages (CD38+CD2±CD3CD16CD68+), and CD3+ T cells (CD8+ and rare CD4+), while B cells are virtually undetectable [11, 49, 50]. The increase in leukocyte numbers during the initial stage of pregnancy suggests that influx and/or proliferation of decidual leukocytes is under endocrine influence. Intimate contact between EVT cells and decidual leukocytes has been demonstrated by electron microscopy and immunohistochemistry, suggesting that there are paracrine interactions between maternal leukocytes and fetal cells [11, 51].

4. NK Cells and uNK Cells in Human Reproduction

In contrast with T and B cells, NK cells do not express somatically rearranged antigen-specific receptors [52]. The functions of NK cells are cell lysis and cytokine production, with individual cells having single or dual competence. For example, lysis is directed against virally infected cells and tumor cells. Interferon (IFN)-γ, which restricts viral infection, is a key cytokine product [53, 54]. The number of peripheral NK cells is decreased in pregnant women compared with nonpregnant women [55, 56], as is IFN-γ production [14].

uNK cells are essentially activated cytokine-producing NK cells [57] that share many characteristics with NK cells. Most peripheral NK cells express the surface marker CD16, an immunoglobulin (Ig) receptor, and have low expression of CD56, an adhesion molecule. In contrast, about 1% of peripheral lymphocytes are CD16CD56bright NK cells, and these CD16+CD56+ NK cells express high amounts of the vascular addressin L-selectin [58]. However, in humans, most uNK cells are CD56bright, but lack CD16 and L-selectin [59]. In women, uNK cells differentiate during every menstrual cycle, 3–5 days after the luteinizing hormone surge [60, 61]. The uNK cells may regulate trophoblast invasion into the decidua, myometrium, and uterine spiral arteries [62]. Postmitotic uNK cells are widely distributed within the decidua basalis, commonly (more than one quarter) associated intramurally and intraluminally with spiral arteries. From mid gestation, the number of uNK cells decreases. It appears that during the first half of gestation, uNK cells contribute to and sustain important changes in the maternal placental bed [54] by producing various soluble products including the angiogenic cytokines angiopoietin-2 and vascular endothelial growth factor [62]. In summary, uNK cells are appropriate residents of the maternal-fetal interface because of their unique function in supporting the adaptation of the blood vessels of the pregnant uterus [63].

5. Macrophages in Pregnancy

Macrophages present within the decidual immune cells during pregnancy have the potential to regulate divergent demands: maintenance of immune tolerance toward allogeneic fetal antigens and defense against the constant risk of infection by ascending and blood-borne pathogens [64]. The functional maturation of macrophages has been revisualized in a manner analogous to the well-supported concept of T helper (Th)1/Th2 polarization of effector T cells, by subcategorizing macrophage effector phenotypes as either M1 or M2 [65, 66]. Macrophages activated under the influence of proinflammatory cytokines and lipopolysaccharide are categorized as M1 type, secrete tumor necrosis factor (TNF) and interleukin (IL)-12, and participate in the progression of inflammation. In contrast, M2 macrophages are polarized by exposure to a milieu containing Th2 cytokines (IL-4, IL-10, and IL-13) and glucocorticoids [67]. M2 polarization is characterized by enhanced expression of innate immunity receptors, including scavenger receptors and the macrophage mannose receptor, as well as an upregulation of arginase activity, which counteracts nitric oxide synthesis [68]. In addition, M2 macrophages exhibit increased secretion of IL-1 receptor antagonist [69] and a reduction in IL-12 production that contributes to the functions of M2 macrophages in tissue repair and anti-inflammation [67]. The M2 polarization of decidual macrophages isolated from normal pregnancies indicates that their immunosuppressive activities are required for the maintenance of immunologic homeostasis during pregnancy. Simultaneously, recognition of hazardous microbes via toll-like receptors (TLRs) and C-type lectin receptors (CLRs) on macrophages is an essential mechanism for host defense in the decidua. Houser et al. propose two distinct subsets of CD14+ decidual macrophages in first-trimester decidual tissue, CD11cHI, and CD11cLO, which do not fit the conventional M1/M2 categorization [70]. CD11cHI decidual macrophages express genes associated with lipid metabolism and inflammation, whereas CD11cLO decidual macrophages express genes associated with extracellular matrix formation, muscle regulation, and tissue growth. The CD11cHI decidual macrophages also differ from CD11cLO decidual macrophages in their ability to process protein antigens and are likely to be the major APCs in the decidua. Moreover, these populations each secrete both proinflammatory and anti-inflammatory cytokines that may contribute to the balance that establishes maternal-fetal tolerance [70].

The M2 polarization of decidual macrophages isolated from normal pregnancies indicates that their immunosuppressive activities are required for the maintenance of immunologic homeostasis during pregnancy, while the recognition of dangerous microbes via TLRs and CLRs on macrophages is a key mechanism for host defense in the decidua. The remarkable phenotypic plasticity of uterine macrophages allows a balance of these seemingly discrepant activities, and defects in uterine macrophage function are closely linked to the pathophysiology of abnormal gestations, including those complicated by preeclampsia and preterm delivery [64].

6. Immune Tolerance and the Th Milieu during Human Reproduction

A successful pregnancy is the consequence of numerous complex interactions between the receptive uterus and the mature blastocyst under immunohormonal control [71, 72]. The Th1/Th2 ratio reaches a peak in the proliferative endometrium, significantly declines during the secretory phase and is at its lowest level in the early pregnancy decidua [73]. During the early phase of pregnancy, a successful implantation occurs in a proinflammatory microenvironment, and a Th1-type response is followed by a shift to Th2 to control endocrine and immune interactions [7476]. Several cytokines such as TNF-α and IL-1 induce leukemia inhibitory factor expression in the stroma and epithelial cells, and through their receptors provide paracrine signals to both embryonic tissues and uterine epithelium during implantation [77]. Th1 responses may be suppressed during human pregnancy via downregulation of nuclear factor (NF)-κB and T-bet transcription [78]. In addition, progesterone stimulates a Th2-type response, reduces inflammatory cytokines, and represses (potentially deleterious) allogeneic responses, conferring fetal survival [79, 80].

Decidual CD4+CD25+ T regulatory cells (Tregs) constitute about 14% of the total decidual CD4+ T cells and express glucocorticoid TNF receptor-related protein, OX40, and cytotoxic T lymphocyte antigen (CTLA)-4 [81]. CTLA-4 expression on Tregs may augment indoleamine 2,3-dioxygenase (IDO) expression by decidual and peripheral blood DCs and monocytes [82]. IDO is involved in maternal tolerance of the fetus by restraining the availability of tryptophan to T cells in situ in the uterine microenvironment [83]. Human pregnancy also involves expression of L-arginase, which exhausts arginine in the fetal-placental microenvironment, thus limiting maternal T-cell activity [84].

While uNK cells, macrophages, and DCs aid in orchestrating the balance between pro- and anti-inflammatory milieus over the course of gestation in humans, human decidua has also recently been shown to contain a small population of immature myeloid DCs [85]. Tregs in the uterus are thought to be mainly immunosuppressive. Decidual CD14+ cells express HLA-DR, but low levels of the costimulatory molecules CD80/CD86, suggesting that they could induce Tregs. The current recognized hypothesis predicts that the potential of trophoblastic antigens to induce a natural and tolerogenic maternal response engages Tregs, cytokines, chemokines, IDO, and galectin-1 derived from the fetoplacental unit [8688], which suggests a possible strategy to treat pathological pregnancy via immunoregulation.

7. The Role of Chemokines in Successful Pregnancy

Chemokines are another important component that are involved in the complex immune network of the fetoplacental unit by adapting normal T cell trafficking and modulating the inflammatory process [89, 90]. We highlight CCL5 (also known as regulated upon activation, normal T cell expressed, and secreted (RANTES)), a proinflammatory chemokine that plays a part in the Th1 response, contributing to a tolerogenic response at immune-privileged sites in murine models, and which might function as an essential modulator of alloantigen-specific T-cell responses during normal pregnancy [91, 92]. Successful pregnancy is accompanied by an increase in RANTES serum levels, whereas these were found to be diminished in patients with recurrent spontaneous abortions [93]. In addition, Ramhorst et al. demonstrated, after treating Ishikawa cells—a human endocervical cell line—with recombinant RANTES and CCR5 (a receptor for RANTES), that there was a decrease in mRNA for CXCR4 (a chemokine receptor associated with a Th2 response) that correlated with an increase in expression of T-bet (the main transcription factor involved in development of a Th1 response) [94]. They also demonstrated that RANTES specifically suppresses alloactivated maternal T cells [95]. Thus, the high levels of progesterone present during normal human pregnancy, particularly at the maternal-fetal interface, would be predicted to promote RANTES production to levels required for the local induction of a tolerogenic immune response. This would suggest that RANTES may play an important role during maternal-fetal crosstalk, allowing trophoblast cell survival and a maternal tolerogenic response [96].

Evidence obtained either in vitro or in vivo has shown that three chemokine receptors, structurally related to signaling receptors, but incapable of activating signal transduction, the Duffy Antigen Receptor for Chemokines (DARC), D6, and CCX CKR, act as chemokine decoy receptors [97]. The best-known chemokine decoy receptor is the D6 molecule, a seven-transmembrane domain protein that shares 30%–35% sequence identity with signaling chemokine receptors, but cannot induce known chemokine receptor-signaling functions such as chemotaxis [98, 99]. D6 recognizes the majority of inflammatory CC chemokines and targets them for degradation [99]. D6 is strongly expressed by invading trophoblast cells and on the apical surface of syncytiotrophoblast cells [100]. Interestingly, Wessels et al. demonstrated that D6 is expressed in endometrial epithelium, uterine glands, and trophoblast; furthermore, in a model of spontaneous fetal loss in swine, a marked loss of D6 immunoreactivity was observed in arresting versus viable littermate attachment sites [101]. These results suggest that the absence of the scavenging function of D6 results in increased susceptibility to inflammation-driven fetal loss [102].

8. Immunomodulatory Molecules in Threatened Pregnancy

During pregnancy, the maternal immune system is obviously active and, under certain conditions, may contribute to fetal damage/death. Well-defined pathological processes include destruction of fetal erythrocytes (Rh antigen, erythroblastosis) and platelets (Human platelet alloantigens (HPA)-1 and HPA-2, alloimmune thrombocytopenia) by maternal antibodies and infections during pregnancy, where activated macrophages secreting high levels of Th1-type cytokines alter the fragile cytokine balance at the maternal-fetal interface [20, 103]. Takeshita et al. found that adipsin immunoreactivity was detected either at the decidua basalis in normal placentas or at the placental maze in absorbed placentas [104]. However, they also showed that the quantity of adipsin was increased in the absorbed placentas compared with the normal placentas, suggesting that local expression of adipsin has an effect at the maternal-fetal interface and probably plays a role in spontaneous abortion [104].

uNK cells have been suggested to have a critical function in pregnancy by promoting decidual health, appropriate vascularization of implantation sites, and placental size. In the murine pregnant uterus, extravillous cytotrophoblasts have invaded the maternal decidua. While the decidual macrophages or DCs recognize the trophoblast debris, uNK cells may become active and acquire a cytotoxic function like that of peripheral NK cells, propagating an immune attack on fetal organs and leading to abortion or premature fetal loss [105]. Recently, upregulation of Th17 cells and their related cytokines (e.g., IL-17 and IL-23) was observed in the blood and decidual tissues of patients with unexpected abortion [106]. Wang et al. also demonstrated that the suppressive activity of Tregs on Th17 cells was decreased in patients with unexplained recurrent miscarriages, that the ability of Tregs to repress inflammatory cytokine production may be effected by direct cell-cell contact, and that transforming growth factor-β and IL-10 could inhibit the expression of IL-17 [107]. Thus, it is likely that investigation of immunomodulatory molecules during pregnancy could assist in developing strategies for prevention or treatment of abortion or fetal loss. We herein focus on three immunoregulatory strategies: (1) induction of endogenous peroxisome proliferator-activated receptor-γ (PPARγ) to reduce antioxidant stress and its related immunomodulation; (2) delivery of decoy receptor 3 (DcR3) to neutralize LIGHT (lymphotoxin exhibits inducible expression and competes with herpesvirus glycoprotein D for HVEM on T cells, LIGHT also known as TL4 or TNFSF14)/Fas signaling; (3) overexpression of galectin-9 to block the T-cell immunoglobulin mucin (TIM)-3 pathway and its potential immunomodulatory role in threatened pregnancy.

PPARγ is a member of the nuclear receptor superfamily, a group of transcription factors that regulate expression of their target genes upon ligand binding. Endogenous ligands including oxidized fatty acids and prostanoids can bind to and activate the receptor [108]. Barak et al. reviewed the role of PPARγ in the areas of adipocyte and macrophage biology, insulin action, bioenergetics, and inflammation and somewhat surprisingly found that PPARγ plays an essential role in placental biology [109]. PPARγ may also function in modulating fetal membrane signals toward parturition. In addition, Schaiff demonstrated the unique aspects of PPARγ function in trophoblasts, which may have direct implications for the use of PPARγ ligands during pregnancy [110]: PPARγ agonists may decrease the risk of preterm delivery by suppressing the inflammatory response within the fetal membranes. Additional research that focuses on the mechanism of action, molecular targets, and functions of placental PPARγ is paramount for the translation of these potentially beneficial functions of PPARγ into therapeutic use during pregnancy [110]. Linoleic acid is a well-known component of many foods and is present in vegetables, fruits, nuts, grains, and seeds. Linoleic and linolenic acids are easily absorbed by oral intake to allow bioavailability to the plasma and the brain [111]. The conjugated form of linoleic acid, cis-9, trans-11, and a well-researched PPARγ ligand was shown to be formed naturally from linoleic acid by gut flora, especially probiotics [112]. This suggests that appropriate nutrition, such as linoleic acids and linolenic acids combined with probiotics that are able to upregulate PPARγ ligands, could provide benefits favoring an uncomplicated pregnancy.

TIM glycoproteins share common structural motifs, including a signal peptide, Ig domain, mucin domain, transmembrane domain, and intracellular tail, with phosphorylation sites [113]. TIM-3 was originally identified as a Th1-specific cell-surface molecule that downregulates Th1 responses through inducing apoptosis signaling by galectin-9 engagement [113, 114]. These results suggest that TIM-3 may modulate the Th1/Th2 balance. In addition, recent reports show that TIM-3 is also expressed on innate immune cells such as DCs and seems to promote innate immunity [115]. Such features of TIM-3 are consistent with the paradigm of Th1/Th2 shift and the activation of the innate immune system in pregnancy. Zhao et al. showed that in pregnant women, TIM-3 enhances both innate and adaptive immune responses by means of its upregulation in innate immune cells, and abnormalities of TIM-3 in pregnant woman may be deleterious to a normal pregnancy. Therefore, TIM-3 may be an indicator for predicting the risk of abortion in pregnant women [116]. In our recent study, we demonstrated that control of the pathogenic Th1 cell immune response through overexpression of galectin-9 to suppress TIM-3 signaling and downregulate proinflammatory cytokine production can inhibit the progressive destruction of β cells in autoimmune diabetes [117], a finding that may suggest a possible strategy for treatment of threatened pregnancy.

A soluble decoy receptor, DcR3, that binds to FasL and inhibits FasL-induced apoptosis has been identified [118], and FasL and LIGHT are established as ligands of DcR3 [119, 120]. Functionally, DcR3 can block FasL/LIGHT-mediated apoptosis leading to the escape of cells from immune attack. TNF-like ligand 1A (TL1A), the third ligand of DcR3, is a costimulator of T cells that promotes IL-2 responsiveness and increases secretion of proinflammatory cytokines both in vitro and in vivo. In addition, DcR3 suppresses TL1A-induced NF-κB activation and apoptosis [121]. Of note, Gill and Hunt postulate that placental cytotrophoblast cells are protected from LIGHT-mediated apoptosis by both soluble receptor DcR3 and cellular inhibitors of apoptosis-2 to protect human cytotrophoblast cells against LIGHT-mediated apoptosis [122]. In addition, Yen et al. demonstrated that human gestational tissues showed differential production of DcR3, and that decidual DcR3 protein was lower in anembryonic than normal pregnancies [123]. We have shown the immunomodulatory and therapeutic activity of DcR3 in various experimental autoimmune disorders in nonobese diabetic mice [124, 125], experimental autoimmune experimental encephalomyelitis [126], and murine autoimmune crescentic glomerulonephritis [127], suggesting a potential activity of DcR3 in the regulation of successful pregnancies. However, above so-called potential immunomodulatory molecules are only the tips of icebergs in the understandings of the complex immunopathogenic mechanisms of threaten pregnancy. Nevertheless, further studies are essential to clarify these hidden mysteries.

9. Conclusion

The immunologic bond between mother and fetus remains a mystery, although current advances in molecular immunobiology have clarified many of the parameters involved in the fetomaternal interaction during implantation. Experimental models provide major insights in the field of reproductive immunology and the immunomodulation of normal or pathological pregnancy. However, ethical issues concerning the study of the physiology of early pregnancy in humans, together with the difficulty of generalizing animal findings to humans, are basic impediments to the clarification of the implantation process and its subsequent investigation [128].


This work is supported by the National Science Council, Taiwan, ROC (NSC99-3112-B-016-001, NSC99-2320-B-016-001-MY3, NSC100-3112-B-016-001 to H.-K. Sytwu, 99-2314-B-016-002-MY3 to S.-J. Chen) and Tri-Service General Hospital (TSGH-C100-024 and TSGH-C101-009-S03 to S.-J. Chen).


  1. R. E. Billingham, L. Brent, and P. B. Medawar, “Actively acquired tolerance of foreign cells,” Nature, vol. 172, no. 4379, pp. 603–606, 1953. View at: Publisher Site | Google Scholar
  2. R. E. Billingham, L. Brent, and P. B. Medawar, “Actively acquired tolerance' of foreign cells. 1953,” Journal of Immunology, vol. 184, no. 1, pp. 5–8, 2010. View at: Google Scholar
  3. R. M. Zinkernagel and H. Hengartner, “Protective ‘immunity’ by pre-existent neutralizing antibody titers and preactivated T cells but not by so-called ‘immunological memory’,” Immunological Reviews, vol. 211, pp. 310–319, 2006. View at: Publisher Site | Google Scholar
  4. G. Bissenden, N. R. Ling, and P. Mackintosh, “Suppression of mixed lymphocyte reactions by pregnancy serum,” Clinical and Experimental Immunology, vol. 39, no. 1, pp. 195–202, 1980. View at: Google Scholar
  5. R. Finn, St. C. A. Hill, and J. C. Davis, “Feto-maternal bidirectional mixed lymphocyte reaction and survival of fetal allograft,” Lancet, vol. 2, no. 8050, pp. 1200–1202, 1977. View at: Google Scholar
  6. L. K. Harris, “Review: trophoblast-vascular cell interactions in early pregnancy: how to remodel a vessel,” Placenta, vol. 31, pp. S93–S98, 2010. View at: Publisher Site | Google Scholar
  7. L. K. Harris, S. D. Smith, R. J. Keogh et al., “Trophoblast- and vascular smooth muscle cell-derived MMP-12 mediates elastolysis during uterine spiral artery remodeling,” American Journal of Pathology, vol. 177, no. 4, pp. 2103–2115, 2010. View at: Publisher Site | Google Scholar
  8. J. E. Cartwright, R. Fraser, K. Leslie, A. E. Wallace, and J. L. James, “Remodelling at the maternal-fetal interface: relevance to human pregnancy disorders,” Reproduction, vol. 140, no. 6, pp. 803–813, 2010. View at: Publisher Site | Google Scholar
  9. G. S. J. Whitley and J. E. Cartwright, “Cellular and molecular regulation of spiral artery remodelling: lessons from the cardiovascular field,” Placenta, vol. 31, no. 6, pp. 465–474, 2010. View at: Publisher Site | Google Scholar
  10. J. N. Bulmer, “Immune aspects of pathology of the placental bed contributing to pregnancy pathology,” Bailliere's Clinical Obstetrics and Gynaecology, vol. 6, no. 3, pp. 461–488, 1992. View at: Publisher Site | Google Scholar
  11. U. von Rango, “Fetal tolerance in human pregnancy-A crucial balance between acceptance and limitation of trophoblast invasion,” Immunology Letters, vol. 115, no. 1, pp. 21–32, 2008. View at: Publisher Site | Google Scholar
  12. M. Kimatrai, C. Oliver, A. C. Abadía-Molina, J. M. García-Pacheco, and E. G. Olivares, “Contractile activity of human decidual stromal cells,” Journal of Clinical Endocrinology and Metabolism, vol. 88, no. 2, pp. 844–849, 2003. View at: Publisher Site | Google Scholar
  13. M. Kimatrai, O. Blanco, R. Muñoz-Fernández et al., “Contractile activity of human decidual stromal cells. II. Effect of interleukin-10,” Journal of Clinical Endocrinology and Metabolism, vol. 90, no. 11, pp. 6126–6130, 2005. View at: Publisher Site | Google Scholar
  14. A. L. V. van Nieuwenhoven, M. J. Heineman, and M. M. Faas, “The immunology of successful pregnancy,” Human Reproduction Update, vol. 9, no. 4, pp. 347–357, 2003. View at: Publisher Site | Google Scholar
  15. O. Blanco, I. Tirado, R. Munoz-Fernandez et al., “Human decidual stromal cells express HLA-G: effects of cytokines and decidualization,” Human Reproduction, vol. 23, no. 1, pp. 144–152, 2008. View at: Google Scholar
  16. C. Ober, T. Hyslop, S. Elias, L. R. Weitkamp, and W. W. Hauck, “Human leukocyte antigen matching and fetal loss: results of a 10 year prospective study,” Human Reproduction, vol. 13, no. 1, pp. 33–38, 1998. View at: Publisher Site | Google Scholar
  17. A. Blaschitz, H. Hutter, and G. Dohr, “HLA Class I protein expression in the human placenta,” Early Pregnancy, vol. 5, no. 1, pp. 67–69, 2001. View at: Google Scholar
  18. J. J. Van Rood and F. Claas, “Both self and non-inherited maternal HLA antigens influence the immune response,” Immunology Today, vol. 21, no. 6, pp. 269–273, 2000. View at: Publisher Site | Google Scholar
  19. J. S. Hunt and H. T. Orr, “HLA and maternal-fetal recognition,” FASEB Journal, vol. 6, no. 6, pp. 2344–2348, 1992. View at: Google Scholar
  20. J. S. Hunt, M. G. Petroff, R. H. McIntire, and C. Ober, “HLA-G and immune tolerance in pregnancy,” FASEB Journal, vol. 19, no. 7, pp. 681–693, 2005. View at: Publisher Site | Google Scholar
  21. J. E. Lewis, C. B. Coulam, and S. B. Moore, “Immunologic mechanisms in the maternal-fetal relationship,” Mayo Clinic Proceedings, vol. 61, no. 8, pp. 655–665, 1986. View at: Google Scholar
  22. V. M. Braud, D. S. Allan, and A. J. McMichael, “Functions of nonclassical MHC and non-MHC-encoded class I molecules,” Current Opinion in Immunology, vol. 11, no. 1, pp. 100–108, 1999. View at: Publisher Site | Google Scholar
  23. J. S. Hunt, G. K. Andrews, and G. W. Wood, “Normal trophoblasts resist induction of class I HLA,” Journal of Immunology, vol. 138, no. 8, pp. 2481–2487, 2010. View at: Google Scholar
  24. G. Gurka and M. E. Rocklin, “Reproductive immunology,” Journal of the American Medical Association, vol. 258, no. 20, pp. 2983–2987, 1987. View at: Google Scholar
  25. C. W. G. Redman, A. J. McMichael, G. M. Stirrat, C. A. Sunderland, and A. Ting, “Class 1 major histocompatibility complex antigens on human extra-villous trophoblast,” Immunology, vol. 52, no. 3, pp. 457–468, 1984. View at: Google Scholar
  26. S. A. Ellis, I. L. Sargent, C. W. G. Redman, and A. J. McMichael, “Evidence for a novel HLA antigen found on human extravillous trophoblast and a choriocarcinoma cell line,” Immunology, vol. 59, no. 4, pp. 595–601, 1986. View at: Google Scholar
  27. A. King, T. D. Burrows, S. E. Hiby et al., “Surface expression of HLA-C antigen by human extravillous trophoblast,” Placenta, vol. 21, no. 4, pp. 376–387, 2000. View at: Publisher Site | Google Scholar
  28. F. H. J. Claas, Y. Gijbels, J. Van Der Velden-De Munck, and J. J. Van Rood, “Induction of B cell unresponsiveness to noninherited maternal HLA antigens during fetal life,” Science, vol. 241, no. 4874, pp. 1815–1817, 1988. View at: Google Scholar
  29. T. Tilburgs, S. A. Scherjon, B. J. van der Mast et al., “Fetal-maternal HLA-C mismatch is associated with decidual T cell activation and induction of functional T regulatory cells,” Journal of Reproductive Immunology, vol. 82, no. 2, pp. 148–157, 2009. View at: Publisher Site | Google Scholar
  30. M. McMaster, Y. Zhou, S. Shorter et al., “HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation,” Journal of Immunology, vol. 160, no. 12, pp. 5922–5928, 1998. View at: Google Scholar
  31. J. S. Hunt and D. L. Langat, “HLA-G: a human pregnancy-related immunomodulator,” Current Opinion in Pharmacology, vol. 9, no. 4, pp. 462–469, 2009. View at: Publisher Site | Google Scholar
  32. E. D. Carosella, P. Moreau, J. Le Maoult, M. Le Discorde, J. Dausset, and N. Rouas-Freiss, “HLA-G molecules: from maternal-fetal tolerance to tissue acceptance,” Advances in Immunology, vol. 81, pp. 199–252, 2003. View at: Publisher Site | Google Scholar
  33. O. Baricordi, M. Stignani, L. Melchiorri, and R. Rizzo, “HLA-G and inflammatory diseases,” Inflammation and Allergy Drug Targets, vol. 7, no. 2, pp. 67–74, 2008. View at: Publisher Site | Google Scholar
  34. P. Parham, “Immunology: keeping mother at bay,” Current Biology, vol. 6, no. 6, pp. 638–641, 1996. View at: Google Scholar
  35. R. Apps, L. Gardner, A. M. Sharkey, N. Holmes, and A. Moffett, “A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1,” European Journal of Immunology, vol. 37, no. 7, pp. 1924–1937, 2007. View at: Publisher Site | Google Scholar
  36. V. Ristich, S. Liang, W. Zhang, J. Wu, and A. Horuzsko, “Tolerization of dendritic cells by HLA-G,” European Journal of Immunology, vol. 35, no. 4, pp. 1133–1142, 2005. View at: Publisher Site | Google Scholar
  37. N. Rouas-Freiss, A. Naji, A. Durrbach, and E. D. Carosella, “Tolerogenic functions of human leukocyte antigen G: from pregnancy to organ and cell transplantation,” Transplantation, vol. 84, supplement 1, pp. S21–S25, 2007. View at: Publisher Site | Google Scholar
  38. R. G. Roussev and C. B. Coulam, “HLA-G and its role in implantation (review),” Journal of Assisted Reproduction and Genetics, vol. 24, no. 7, pp. 288–295, 2007. View at: Publisher Site | Google Scholar
  39. L. E. Noronha and D. F. Antczak, “Maternal immune responses to trophoblast: the contribution of the horse to pregnancy immunology,” American Journal of Reproductive Immunology, vol. 64, no. 4, pp. 231–244, 2010. View at: Publisher Site | Google Scholar
  40. S. J. Bacon, S. A. Ellis, and D. F. Antczak, “Control of expression of major histocompatibility complex genes in horse trophoblast,” Biology of Reproduction, vol. 66, no. 6, pp. 1612–1620, 2002. View at: Google Scholar
  41. W. L. Donaldson, J. G. Oriol, C. L. Pelkaus, and D. F. Antczak, “Paternal and maternal major histocompatibility complex class I antigens are expressed co-dominantly by equine trophoblast,” Placenta, vol. 15, no. 2, pp. 123–135, 1994. View at: Google Scholar
  42. N. Rouas-Freiss, R. M. B. Gonçalves, C. Menier, J. Dausset, and E. D. Carosella, “Direct evidence to support the role of HLA-G in protecting the fetus from maternal uterine natural killer cytolysis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 21, pp. 11520–11525, 1997. View at: Publisher Site | Google Scholar
  43. V. M. Braud, D. S. J. Allan, C. A. O'Callaghan et al., “HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C,” Nature, vol. 391, no. 6669, pp. 795–799, 1998. View at: Publisher Site | Google Scholar
  44. J. M. Baker, A. I. Bamford, and D. F. Antczak, “Modulation of allospecific CTL responses during pregnancy in equids: an immunological barrier to interspecies matings?” Journal of Immunology, vol. 162, no. 8, pp. 4496–4501, 1999. View at: Google Scholar
  45. R. G. Lea and A. E. Bolton, “The effect of horse placental tissue extracts and equine chorionic gonadotrophin on the proliferation of horse lymphocytes stimulated in vitro,” Journal of Reproductive Immunology, vol. 19, no. 1, pp. 13–23, 1991. View at: Publisher Site | Google Scholar
  46. M. J. B. F. Flaminio and D. F. Antczak, “Inhibition of lymphocyte proliferation and activation: a mechanism used by equine invasive trophoblast to escape the maternal immune response,” Placenta, vol. 26, no. 2-3, pp. 148–159, 2005. View at: Publisher Site | Google Scholar
  47. J. L. Strominger, “Human decidual lymphocytes and the immunobiology of pregnancy,” Journal of Reproductive Immunology, vol. 62, no. 1-2, pp. 17–18, 2004. View at: Publisher Site | Google Scholar
  48. D. Sanguansermsri and S. Pongcharoen, “Pregnancy immunology: decidual immune cells,” Asian Pacific Journal of Allergy and Immunology, vol. 26, no. 2-3, pp. 171–181, 2008. View at: Google Scholar
  49. U. Von Rango, I. Classen-Linke, S. Kertschanska, B. Kemp, and H. M. Beier, “Effects of trophoblast invasion on the distribution of leukocytes in uterine and tubal implantation sites,” Fertility and Sterility, vol. 76, no. 1, pp. 116–124, 2001. View at: Publisher Site | Google Scholar
  50. M. P. Piccinni, “T cells in normal pregnancy and recurrent pregnancy loss,” Reproductive BioMedicine Online, vol. 13, no. 6, article no. 2439, pp. 840–844, 2006. View at: Google Scholar
  51. M. Tekelioglu Uysal, R. G. Edwards, and H. A. Kisnisci, “Ultrastructural relationships between decidua, trophoblast and lymphocytes at the beginning of human pregnancy,” Journal of Reproduction and Fertility, vol. 42, no. 3, pp. 431–438, 1975. View at: Google Scholar
  52. K. Natarajan, N. Dimasi, J. Wang, R. A. Mariuzza, and D. H. Margulies, “Structure and function of natural killer cell receptors: multiple molecular solutions to self, nonself discrimination,” Annual Review of Immunology, vol. 20, pp. 853–885, 2002. View at: Publisher Site | Google Scholar
  53. G. Trinchieri, “Natural killer cells wear different hats: effector cells of innate resistance and regulatory cells of adaptive immunity and of hematopoiesis,” Seminars in Immunology, vol. 7, no. 2, pp. 83–88, 1995. View at: Google Scholar
  54. B. A. Croy, H. He, S. Esadeg et al., “Uterine natural killer cells: insights into their cellular and molecular biology from mouse modelling,” Reproduction, vol. 126, no. 2, pp. 149–160, 2003. View at: Google Scholar
  55. M. Watanabe, Y. Iwatani, T. Kaneda et al., “Changes in T, B, and NK lymphocyte subsets during and after normal pregnancy,” American Journal of Reproductive Immunology, vol. 37, no. 5, pp. 368–377, 1997. View at: Google Scholar
  56. M. Kühnert, R. Strohmeier, M. Stegmüller, and E. Halberstadt, “Changes in lymphocyte subsets during normal pregnancy,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 76, no. 2, pp. 147–151, 1998. View at: Publisher Site | Google Scholar
  57. A. Moffett-King, “Natural killer cells and pregnancy,” Nature Reviews Immunology, vol. 2, no. 9, pp. 656–663, 2002. View at: Publisher Site | Google Scholar
  58. J. J. Campbell, S. Qin, D. Unutmaz et al., “Unique subpopulations of CD56+ NK and NK-T peripheral blood lymphocytes identified by chemokine receptor expression repertoire,” Journal of Immunology, vol. 166, no. 11, pp. 6477–6482, 2001. View at: Google Scholar
  59. R. F. Searle, R. K. Jones, and J. N. Bulmer, “Phenotypic analysis and proliferative responses of human endometrial granulated lymphocytes during the menstrual cycle,” Biology of Reproduction, vol. 60, no. 4, pp. 871–878, 1999. View at: Google Scholar
  60. A. Ritson and J. N. Bulmer, “Endometrial granulocytes in human decidua react with a natural-killer (NK) cell marker, NKH1,” Immunology, vol. 62, no. 2, pp. 329–331, 1987. View at: Google Scholar
  61. A. King, “Uterine leukocytes and decidualization,” Human Reproduction Update, vol. 6, no. 1, pp. 28–36, 2000. View at: Google Scholar
  62. A. Moffett and C. Loke, “Immunology of placentation in eutherian mammals,” Nature Reviews Immunology, vol. 6, no. 8, pp. 584–594, 2006. View at: Publisher Site | Google Scholar
  63. J. Hanna and O. Mandelboim, “When killers become helpers,” Trends in Immunology, vol. 28, no. 5, pp. 201–206, 2007. View at: Publisher Site | Google Scholar
  64. T. Nagamatsu and D. J. Schust, “The contribution of macrophages to normal and pathological pregnancies,” American Journal of Reproductive Immunology, vol. 63, no. 6, pp. 460–471, 2010. View at: Publisher Site | Google Scholar
  65. C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, “M-1/M-2 macrophages and the Th1/Th2 paradigm,” Journal of Immunology, vol. 164, no. 12, pp. 6166–6173, 2000. View at: Google Scholar
  66. A. Mantovani, A. Sica, and M. Locati, “Macrophage polarization comes of age,” Immunity, vol. 23, no. 4, pp. 344–346, 2005. View at: Publisher Site | Google Scholar
  67. S. Gordon, “Alternative activation of macrophages,” Nature Reviews Immunology, vol. 3, no. 1, pp. 23–35, 2003. View at: Publisher Site | Google Scholar
  68. M. Munder, K. Eichmann, and M. Modolell, “Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype,” Journal of Immunology, vol. 160, no. 11, pp. 5347–5354, 1998. View at: Google Scholar
  69. M. J. Fenton, J. A. Buras, and R. P. Donnelly, “IL-4 reciprocally regulates IL-1 and IL-1 receptor antagonist expression in human monocytes,” Journal of Immunology, vol. 149, no. 4, pp. 1283–1288, 1992. View at: Google Scholar
  70. B. L. Houser, T. Tilburgs, J. Hill, M. L. Nicotra, and J. L. Strominger, “Two unique human decidual macrophage populations,” Journal of Immunology, vol. 186, no. 4, pp. 2633–2642, 2011. View at: Google Scholar
  71. S. Saito, “Cytokine network at the feto-maternal interface,” Journal of Reproductive Immunology, vol. 47, no. 2, pp. 87–103, 2000. View at: Publisher Site | Google Scholar
  72. O. Thellin, B. Coumans, W. Zorzi, A. Igout, and E. Heinen, “Tolerance to the foeto-placental ‘graft’: ten ways to support a child for nine months,” Current Opinion in Immunology, vol. 12, no. 6, pp. 731–737, 2000. View at: Publisher Site | Google Scholar
  73. S. Saito, N. Tsukaguchi, T. Hasegawa, T. Michimata, H. Tsuda, and N. Narita, “Distribution of Th1, Th2, and Th0 and the Th1/Th2 cell ratios in human peripheral and endometrial T cells,” American Journal of Reproductive Immunology, vol. 42, no. 4, pp. 240–245, 1999. View at: Google Scholar
  74. S. Fest, P. B. Aldo, V. M. Abrahams et al., “Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy,” American Journal of Reproductive Immunology, vol. 57, no. 1, pp. 55–66, 2007. View at: Publisher Site | Google Scholar
  75. D. A. Clark, G. Chaouat, D. A. Clark, and R. M. Gorczynski, “Thinking outside the box: mechanisms of environmental selective pressures on the outcome of the materno-fetal relationship,” American Journal of Reproductive Immunology, vol. 47, no. 5, pp. 275–282, 2002. View at: Publisher Site | Google Scholar
  76. G. Chaouat, N. Ledée-Bataille, S. Dubanchet, S. Zourbas, O. Sandra, and J. Martal, “Th1/Th2 paradigm in pregnancy: paradigm lost? Cytokines in pregnancy/early abortion: reexamining the Th1/Th2 paradigm,” International Archives of Allergy and Immunology, vol. 134, no. 2, pp. 93–119, 2004. View at: Publisher Site | Google Scholar
  77. H. Song and H. Lim, “Evidence for heterodimeric association of leukemia inhibitory factor (LIF) receptor and gp130 in the mouse uterus for LIF signaling during blastocyst implantation,” Reproduction, vol. 131, no. 2, pp. 341–349, 2006. View at: Publisher Site | Google Scholar
  78. S. A. McCracken, K. Hadfield, Z. Rahimi, E. D. Gallery, and J. M. Morris, “NF-κB-regulated suppression of T-bet in T cells represses Th1 immune responses in pregnancy,” European Journal of Immunology, vol. 37, no. 5, pp. 1386–1396, 2007. View at: Publisher Site | Google Scholar
  79. H. Miyaura and M. Iwata, “Direct and indirect inhibition of Th1 development by progesterone and glucocorticoids,” Journal of Immunology, vol. 168, no. 3, pp. 1087–1094, 2002. View at: Google Scholar
  80. K. W. Beagley and C. M. Gockel, “Regulation of innate and adaptive immunity by the female sex hormones oestradiol and progesterone,” FEMS Immunology and Medical Microbiology, vol. 38, no. 1, pp. 13–22, 2003. View at: Publisher Site | Google Scholar
  81. J. Heikkinen, M. Möttönen, A. Alanen, and O. Lassila, “Phenotypic characterization of regulatory T cells in the human decidua,” Clinical and Experimental Immunology, vol. 136, no. 2, pp. 373–378, 2004. View at: Publisher Site | Google Scholar
  82. N. Miwa, S. Hayakawa, S. Miyazaki et al., “IDO expression on decidual and peripheral blood dendritic cells and monocytes/macrophages after treatment with CTLA-4 or interferon-γ increase in normal pregnancy but decrease in spontaneous abortion,” Molecular Human Reproduction, vol. 11, no. 12, pp. 865–870, 2005. View at: Publisher Site | Google Scholar
  83. A. L. Mellor, J. Sivakumar, P. Chandler et al., “Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy,” Nature Immunology, vol. 2, no. 1, pp. 64–68, 2001. View at: Publisher Site | Google Scholar
  84. P. Kropf, D. Baud, S. E. Marshall et al., “Arginase activity mediates reversible T cell hyporesponsiveness in human pregnancy,” European Journal of Immunology, vol. 37, no. 4, pp. 935–945, 2007. View at: Publisher Site | Google Scholar
  85. L. Gardner and A. Moffett, “Dendritic cells in the human decidua,” Biology of Reproduction, vol. 69, no. 4, pp. 1438–1446, 2003. View at: Publisher Site | Google Scholar
  86. V. R. Aluvihare, M. Kallikourdis, and A. G. Betz, “Regulatory T cells mediate maternal tolerance to the fetus,” Nature Immunology, vol. 5, no. 3, pp. 266–271, 2004. View at: Publisher Site | Google Scholar
  87. S. M. Blois, J. M. Ilarregui, M. Tometten et al., “A pivotal role for galectin-1 in fetomaternal tolerance,” Nature Medicine, vol. 13, no. 12, pp. 1450–1457, 2007. View at: Publisher Site | Google Scholar
  88. P. Terness, M. Kallikourdis, A. G. Betz, G. A. Rabinovich, S. Saito, and D. A. Clark, “Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells,” American Journal of Reproductive Immunology, vol. 58, no. 3, pp. 238–254, 2007. View at: Publisher Site | Google Scholar
  89. D. Rossi and A. Zlotnik, “The biology of chemokines and their receptors,” Annual Review of Immunology, vol. 18, pp. 217–243, 2000. View at: Publisher Site | Google Scholar
  90. S. A. Luther and J. G. Cyster, “Chemokines as regulators of T cell differentiation,” Nature Immunology, vol. 2, no. 2, pp. 102–107, 2001. View at: Publisher Site | Google Scholar
  91. D. E. Faunce and J. Stein-Streilein, “NKT cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance,” Journal of Immunology, vol. 169, no. 1, pp. 31–38, 2002. View at: Google Scholar
  92. D. Hornung, F. Bentzien, D. Wallwiener, L. Kiesel, and R. N. Taylor, “Chemokine bioactivity of RANTES in endometriotic and normal endometrial stromal cells and peritoneal fluid,” Molecular Human Reproduction, vol. 7, no. 2, pp. 163–168, 2001. View at: Google Scholar
  93. L. Fraccaroli, J. Alfieri, C. P. Leiros, and R. Ramhorst, “Immunomodulatory effects of chemokines during the early implantation window,” Frontiers in Bioscience, vol. 1, pp. 288–298, 2009. View at: Google Scholar
  94. R. Ramhorst, G. Gutiérrez, A. Corigliano, G. Junovich, and L. Fainboim, “Implication of RANTES in the modulation of alloimmune response by progesterone during pregnancy,” American Journal of Reproductive Immunology, vol. 57, no. 2, pp. 147–152, 2007. View at: Publisher Site | Google Scholar
  95. R. Ramhorst, R. Patel, A. Corigliano, J. J. Etchepareborda, L. Fainboim, and D. Schust, “Induction of maternal tolerance to fetal alloantigens by RANTES production,” American Journal of Reproductive Immunology, vol. 56, no. 5-6, pp. 302–311, 2006. View at: Publisher Site | Google Scholar
  96. L. Fraccaroli, J. Alfieri, L. Larocca et al., “A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation,” Human Reproduction, vol. 24, no. 1, pp. 166–175, 2009. View at: Publisher Site | Google Scholar
  97. A. Mantovani, R. Bonecchi, and M. Locati, “Tuning inflammation and immunity by chemokine sequestration: decoys and more,” Nature Reviews Immunology, vol. 6, no. 12, pp. 907–918, 2006. View at: Publisher Site | Google Scholar
  98. R. J. B. Nibbs, S. M. Wylie, J. Yang, N. R. Landau, and G. J. Graham, “Cloning and characterization of a novel promiscuous human β-chemokine receptor D6,” Journal of Biological Chemistry, vol. 272, no. 51, pp. 32078–32083, 1997. View at: Publisher Site | Google Scholar
  99. R. Bonecchi, M. Locati, E. Galliera et al., “Differential recognition and scavenging of native and truncated macrophage-derived chemokine (Macrophage-Derived Chemokine/CC Chemokine Ligand 22) by the D6 decoy receptor,” Journal of Immunology, vol. 172, no. 8, pp. 4972–4976, 2004. View at: Google Scholar
  100. Y. M. De La Torre, C. Buracchi, E. M. Borroni et al., “Protection against inflammation- and autoantibody-caused fetal loss by the chemokine decoy receptor D6,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 7, pp. 2319–2324, 2007. View at: Publisher Site | Google Scholar
  101. J. M. Wessels, N. F. Linton, A. B. Croy, and C. Tayade, “A review of molecular contrasts between arresting and viable porcine attachment sites,” American Journal of Reproductive Immunology, vol. 58, no. 6, pp. 470–480, 2007. View at: Publisher Site | Google Scholar
  102. C. Garlanda, V. Maina, Y. Martinez de la Torre, M. Nebuloni, and M. Locati, “Inflammatory reaction and implantation: the new entries PTX3 and D6,” Placenta, vol. 29, no. 2, pp. 129–134, 2008. View at: Publisher Site | Google Scholar
  103. N. Genetet, B. Genetet, V. Amice, and R. Fauchet, “Allogeneic responses in vitro induced by fetomaternal alloimmunization,” American Journal of Reproductive Immunology, vol. 2, no. 2, pp. 90–96, 1982. View at: Google Scholar
  104. A. Takeshita, T. Kondo, T. Okada, and K. T. Kusakabe, “Elevation of adipsin, a complement activating factor, in the mouse placenta during spontaneous abortion,” Journal of Reproduction and Development, vol. 56, no. 5, pp. 508–514, 2010. View at: Publisher Site | Google Scholar
  105. O. Nakamura, “Children's immunology, what can we learn from animal studies (1): decidual cells induce specific immune system of feto-maternal interface,” The Journal of Toxicological Sciences, vol. 34, supplement 2, pp. S331–S339, 2009. View at: Google Scholar
  106. W. J. Wang, C. F. Hao, Yi-Lin et al., “Increased prevalence of T helper 17 (Th17) cells in peripheral blood and decidua in unexplained recurrent spontaneous abortion patients,” Journal of Reproductive Immunology, vol. 84, no. 2, pp. 164–170, 2010. View at: Publisher Site | Google Scholar
  107. W. J. Wang, C. F. Hao, Q. L. Qu, X. Wang, L. H. Qiu, and Q. D. Lin, “The deregulation of regulatory T cells on interleukin-17-producing T helper cells in patients with unexplained early recurrent miscarriage,” Human Reproduction, vol. 25, no. 10, pp. 2591–2596, 1982. View at: Google Scholar
  108. A. Szanto and L. Nagy, “The many faces of PPARγ: anti-inflammatory by any means?” Immunobiology, vol. 213, no. 9-10, pp. 789–803, 2008. View at: Publisher Site | Google Scholar
  109. Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at: Publisher Site | Google Scholar
  110. W. T. Schaiff, Y. Barak, and Y. Sadovsky, “The pleiotropic function of PPARγ in the placenta,” Molecular and Cellular Endocrinology, vol. 249, no. 1-2, pp. 10–15, 2006. View at: Publisher Site | Google Scholar
  111. H. Martin, “Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components,” Mutation Research, vol. 669, no. 1-2, pp. 1–7, 2009. View at: Publisher Site | Google Scholar
  112. J. B. Ewaschuk, J. W. Walker, H. Diaz, and K. L. Madsen, “Bioproduction of conjugated linoleic acid by probiotic bacteria occurs in vitro and in vivo in mice,” Journal of Nutrition, vol. 136, no. 6, pp. 1483–1487, 2006. View at: Google Scholar
  113. V. K. Kuchroo, J. H. Meyers, D. T. Umetsu, and R. H. DeKruyff, “TIM family of genes in immunity and tolerance,” Advances in Immunology, vol. 91, pp. 227–249, 2006. View at: Publisher Site | Google Scholar
  114. L. Monney, C. A. Sabatos, J. L. Gaglia et al., “Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease,” Nature, vol. 415, no. 6871, pp. 536–541, 2002. View at: Publisher Site | Google Scholar
  115. A. C. Anderson, D. E. Anderson, L. Bregoli et al., “Promotion of tissue inflammation by the immune receptor Tim-3 expressed on innate immune cells,” Science, vol. 318, no. 5853, pp. 1141–1143, 2007. View at: Publisher Site | Google Scholar
  116. J. Zhao, Z. Lei, Y. Liu et al., “Human pregnancy up-regulates Tim-3 in innate immune cells for systemic immunity,” Journal of Immunology, vol. 182, no. 10, pp. 6618–6624, 2009. View at: Publisher Site | Google Scholar
  117. F. C. Chou, S. J. Shieh, and H. K. Sytwu, “Attenuation of Th1 response through galectin-9 and T-cell Ig mucin 3 interaction inhibits autoimmune diabetes in NOD mice,” European Journal of Immunology, vol. 39, no. 9, pp. 2403–2411, 2009. View at: Publisher Site | Google Scholar
  118. R. M. Pitti, S. A. Marsters, D. A. Lawrence et al., “Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer,” Nature, vol. 396, no. 6712, pp. 699–703, 1998. View at: Publisher Site | Google Scholar
  119. K. Y. Yu, B. Kwon, J. Ni, Y. Zhai, R. Ebner, and B. S. Kwon, “A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis,” Journal of Biological Chemistry, vol. 274, no. 20, pp. 13733–13736, 1999. View at: Publisher Site | Google Scholar
  120. J. Zhang, T. W. Salcedo, X. Wan et al., “Modulation of T-cell responses to alloantigens by TR6/DcR3,” Journal of Clinical Investigation, vol. 107, no. 11, pp. 1459–1468, 2001. View at: Google Scholar
  121. T. S. Migone, J. Zhang, X. Luo et al., “TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator,” Immunity, vol. 16, no. 3, pp. 479–492, 2002. View at: Publisher Site | Google Scholar
  122. R. M. Gill and J. S. Hunt, “Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis,” American Journal of Pathology, vol. 165, no. 1, pp. 309–317, 2004. View at: Google Scholar
  123. B. L. Yen, J. C. Chan, K. J. Liu et al., “Brief report-Human embryonic stem cell-derived mesenchymal progenitors possess strong immunosuppressive effects toward natural killer cells as well as T lymphocytes,” Stem Cells, vol. 27, no. 2, pp. 451–456, 2009. View at: Publisher Site | Google Scholar
  124. H. H. Sung, J. H. Juang, Y. C. Lin et al., “Transgenic expression of decoy receptor 3 protects islets from spontaneous and chemical-induced autoimmune destruction in nonobese diabetic mice,” Journal of Experimental Medicine, vol. 199, no. 8, pp. 1143–1151, 2004. View at: Publisher Site | Google Scholar
  125. S. F. Wu, T. M. Liu, Y. C. Lin et al., “Immunomodulatory effect of decoy receptor 3 on the differentiation and function of bone marrow-derived dendritic cells in nonobese diabetic mice: from regulatory mechanism to clinical implication,” Journal of Leukocyte Biology, vol. 75, no. 2, pp. 293–306, 2004. View at: Publisher Site | Google Scholar
  126. S. J. Chen, Y. L. Wang, J. H. Kao et al., “Decoy receptor 3 ameliorates experimental autoimmune encephalomyelitis by directly counteracting local inflammation and downregulating Th17 cells,” Molecular Immunology, vol. 47, no. 2-3, pp. 567–574, 2009. View at: Publisher Site | Google Scholar
  127. S. M. Ka, H. K. Sytwu, D. M. Chang, S. L. Hsieh, P. Y. Tsai, and A. Chen, “Decoy receptor 3 ameliorates an autoimmune crescentic glomerulonephritis model in mice,” Journal of the American Society of Nephrology, vol. 18, no. 9, pp. 2473–2485, 2007. View at: Publisher Site | Google Scholar
  128. A. Makrigiannakis, M. Karamouti, P. Drakakis, D. Loutradis, and A. Antsaklis, “Fetomaternal immunotolerance,” American Journal of Reproductive Immunology, vol. 60, no. 6, pp. 482–496, 2008. View at: Publisher Site | Google Scholar

Copyright © 2012 Shyi-Jou Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.